<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290923</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01140</org_study_id>
    <nct_id>NCT04290923</nct_id>
  </id_info>
  <brief_title>Determination of Blood Tumor Cells</brief_title>
  <official_title>Determination of Blood Tumor Cells Using Magnetic Nanoparticles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo
      in patients blood .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are
      designed to interact with epithelial tumor cells. Aim of this study is to see if circulating
      tumor cells (EpCAM as marker)can be removed out of the blood with the help of these
      particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked
      to test their blood.

      Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid
      tumors in the blood such as lymphoma or leukemia (CD52 as marker).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CTC / lymphocytes removed</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <condition>Abnormalities Cell Epithelial</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample at one single time point
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Criterion for the enrollment is the presence of an epithelial cell carcinoma or the
        presence of a non-solid tumor (i.e. lymphoma or leucemia)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)

        Exclusion Criteria:

        Inability to understand the language of the center (German)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Beatrice H Beck Schimmer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatrice H Beck Schimmer, Prof</last_name>
    <phone>+41442552696</phone>
    <phone_ext>+41442552696</phone_ext>
    <email>beatrice.beck@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin H Schläpfer, PD</last_name>
    <phone>+41442554690</phone>
    <phone_ext>+41442552696</phone_ext>
    <email>martin.schlaepfer@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Beck Schimmer, Prof. MD</last_name>
      <phone>+41 44 255 2032</phone>
    </contact>
    <investigator>
      <last_name>Schläpfer Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91.</citation>
    <PMID>15317891</PMID>
  </reference>
  <reference>
    <citation>Herrmann IK, Bernabei RE, Urner M, Grass RN, Beck-Schimmer B, Stark WJ. Device for continuous extracorporeal blood purification using target-specific metal nanomagnets. Nephrol Dial Transplant. 2011 Sep;26(9):2948-54. doi: 10.1093/ndt/gfq846. Epub 2011 Feb 10.</citation>
    <PMID>21310738</PMID>
  </reference>
  <reference>
    <citation>Herrmann IK, Schlegel A, Graf R, Schumacher CM, Senn N, Hasler M, Gschwind S, Hirt AM, Günther D, Clavien PA, Stark WJ, Beck-Schimmer B. Nanomagnet-based removal of lead and digoxin from living rats. Nanoscale. 2013 Sep 21;5(18):8718-23. doi: 10.1039/c3nr02468g.</citation>
    <PMID>23900264</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelial Cell Adhesion Molecule</keyword>
  <keyword>Magnetite Nanoparticles</keyword>
  <keyword>Tumor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

